Viewing data from:

LANTHANUM CARBONATE

ANDA

LANTHANUM CARBONATE | A202329 | ALKEM LABORATORIES LTD

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: FOSRENOL(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 2 NDCs

Highest NADAC/Unit

$3.26

per ea

Lowest NADAC/Unit

$3.07

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
67877025690LANTHANUM CARB 500 MG TAB CHEW	$3.26	EA	Generic	—	2026-08-19
67877025890LANTHANUM CARB 1,000 MG TB CHW	$3.07	EA	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain12 active DMFs3 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

MATRIX PHARMACORP PRIVATE LTDLANTHANUM CARBONATE

DMF 219582008

NATCO PHARMA LTDLANTHANUM CARBONATE DIHYDRATE

DMF 220502008

EXCELLA GMBH AND CO KGLANTHANUM CARBONATE

DMF 220942008

UNIMARK REMEDIES LTDLANTHANUM CARBONATE OCTAHYDRATE

DMF 232542009

SYMED LABS LTDLANTHANUM CARBONATE

DMF 282172014

MATRIX PHARMACORP PRIVATE LTDLANTHANUM CARBONATE (PROCESS 2)

DMF 334082018

ALKEM LABORATORIES LTDLANTHANUM CARBONATE OCTAHYDRATE

DMF 352982020

SOLARA ACTIVE PHARMA SCIENCES LTDLANTHANUM CARBONATE TETRAHYDRATE

DMF 370172022

SOLARA ACTIVE PHARMA SCIENCES LTDLANTHANUM CARBONATE OCTAHYDRATE

DMF 370182022

ZENJI PHARMACEUTICALS (SUZHOU) LTDLANTHANUM CARBONATE

DMF 370582023

ZHEJIANG GUOBANG PHARMACEUTICAL CO LTDLANTHANUM CARBONATE

DMF 393212023

ZENJI PHARMACEUTICALS (RIZHAO) LTDLANTHANUM CARBONATE

DMF 429572025

JOHNSON MATTHEY INCInactiveLANTHANUM CARBONATE

DMF 127221997

BOEHRINGER INGELHEIM CHEMICALS INCInactiveLANTHANUM CARBONATE HYDRATE

DMF 187862005

SIGNA SA DE CVInactiveLANTHANUM CARBONATE HYDRATE

DMF 280082014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — EQ 500MG BASE

0 patents0 exclusivities▴

TABLET, CHEWABLE;ORAL | Approved: Mar 13, 2025

No patent or exclusivity listings for this strength.

#002 — EQ 750MG BASE

0 patents0 exclusivities▾

TABLET, CHEWABLE;ORAL | Approved: Mar 13, 2025

#003 — EQ 1GM BASE

0 patents0 exclusivities▾

TABLET, CHEWABLE;ORAL | Approved: Mar 13, 2025